Therapeutic goals of baseline and escalation therapy for relapsing-Remitting multiple sclerosis;Therapieziele von Basis- und Eskalationstherapien zur Behandlung der schubförmig-remittierenden Multiplen Sklerose

Aktuelle Neurologie

Volumn 39, Issue 7, 2012, Pages 342-350

  Gold, R ^a   Hartung, H P ^b   Stangel, M ^c   Wiendl, H ^d   Zipp, F ^e  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

escalation therapy; multiple sclerosis; therapy

Indexed keywords

FINGOLIMOD; IMMUNOMODULATING AGENT; NATALIZUMAB;

ARTICLE; DISABILITY; DISEASE ACTIVITY; DISEASE COURSE; EARLY INTERVENTION; HUMAN; IMMUNOMODULATION; LONG TERM CARE; MEDICAL DECISION MAKING; MEDICAL EXPERT; MULTIPLE SCLEROSIS; NEUROLOGIST; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT MONITORING; PROFESSIONAL COMPETENCE; PROGNOSIS; QUALITY OF LIFE; TREATMENT PLANNING; WORK CAPACITY;

EID: 84866119687     PISSN: 03024350     EISSN: 14389428     Source Type: Journal    
DOI: 10.1055/s-0032-1305248     Document Type: Article

References (53)

1. Polman CH, O'Connor PW, Havrdova E et al. AFFIRM Investigators A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med: 2006; 354 899 910
2. Kappos L, Radue EW, O'Connor P et al. FREEDOMS Study Group A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med: 2010; 362 387 401
3. Goodman AD, Rossman H, Bar-Or A et al. GLANCE Investigators GLANCE: results of a phase 2, randomized, double-blind, placebo-controlled study. Neurology: 2009; 72 806 812
4. Khatri B, Barkhof F, Comi G et al. TRANSFORMS Study Group Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. Lancet Neurol: 2011; 10 520 529
5. Rudick RA, Stuart WH, Calabresi PA et al. SENTINEL Investigators Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med: 2006; 354 911 923
6. Havrdova E, Galetta S, Hutchinson M et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. Lancet Neurol: 2009; 8 254 260
7. Phillips JT, Giovannoni G, Lublin FD et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis. Mult Scler: 2011; 17 970 979
8. Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci: 2011; 32 83 88
9. Wilken J, Kane R, Sullivan C, Gudesblatt M, Lucas S, Fallis R, Pace A, Kim R. Evakuation of Natalizumab for the relief of multiple sclerosis associated fatigue. 62nd American Academy of Neurology Annual Meeting: 2010; Poster P06.142
10. Balcer L, Galletta S, Polman CH, Rucick R, Eggenberger E, Calabresi P, Munschauer F, Zhang A, Hyde R. Low-contrast letter acuity detects visual function improvement in a phase 3 trial of natalizumab monotherapy. 16th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Poster P541
11. Olofsson S, Wickström A, Häger Glenngård A et al. Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment. BioDrugs: 2011; 25 299 306
12. Stadler B, Ortler S, Meergans M, Hohlfeld R. Die Behandlung mit Fingolimod erhöht den Anteil von Patienten mit Multipler Sklerose, die frei von Krankheitsaktivität sind: post-hoc Ergebnisse aus einer placebokontrollierten Phase-III-Studie (FREEDOMS). DGN: 2011; Poster 397
13. ®), Juni 2011
14. ®), März 2011
15. Rudick RA, Polman CH. Current approaches to the identification and management of breakthrough disease in patients with multiple sclerosis. Lancet Neurol: 2009; 8 545 559
16. Scalfari A, Neuhaus A, Degenhardt A et al. The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability. Brain: 2010; 133 1914 1929
17. Weinshenker BG, Bass B, Rice GP et al. The natural history of multiple sclerosis: a geographically based study. 2. Predictive value of the early clinical course. Brain: 1989; 112 1419 1428
18. Weiner HL, Guttmann CR, Khoury SJ et al. Serial magnetic resonance imaging in multiple sclerosis: correlation with attacks, disability, and disease stage. J Neuroimmunol: 2000; 104 164 173
19. Prosperini L, Gallo V, Petsas N et al. One-year MRI scan predicts clinical response to interferon beta in multiple sclerosis. Eur J Neurol: 2009; 16 1202 1209
20. Brex PA, Ciccarelli O, O'Riordan JI et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med: 2002; 346 158 164
21. Fisniku LK, Brex PA, Altmann DR et al. Disability and T2 MRI lesions: a 20-year follow-up of patients with relapse onset of multiple sclerosis. Brain: 2008; 131 808 817
22. Hirst C, Ingram G, Pearson O et al. Contribution of relapses to disability in multiple sclerosis. J Neurol: 2008; 255 280 287
23. Leray E, Yaouanq J, Le Page E et al. Evidence for a two-stage disability progression in multiple sclerosis. Brain: 2010; 133 1900 1913
24. Confavreux C, Vukusic S, Moreau T et al. Relapses and progression of disability in multiple sclerosis. Brain: 2000; 343 1430 1438
25. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain: 2003; 126 770 782
26. Tremlett H, Yousefi M, Devonshire V et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology: 2009; 73 1616 1623
27. Kuhlmann T, Lingfeld G, Bitsch A et al. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain: 2002; 125 2202 2212
28. Goldschmidt T, Antel J, König FB et al. Remyelination capacity of the MS brain decreases with disease chronicity. Neurology: 2009; 72 1914 1921
29. Coles AJ, Wing MG, Molyneux P et al. Monoclonal antibody treatment exposes three mechanisms underlying the clinical course of multiple sclerosis. Ann Neurol: 1999; 46 296 304
30. ® Observational Program (TOP): Langzeitsicherheit und -wirksamkeit von Natalizumab bei Patienten mit schubförmig-remittierender Multipler Sklerose. 84. Kongress der Deutschen Gesellschaft für Neurologie; P414
31. Biogen Idec, Data on file
32. Mäurer M, Dachsel R, Domke S et al. TYPIC Study Investigators Health care situation of patients with relapsing-remitting multiple sclerosis receiving immunomodulatory therapy: a retrospective survey of more than 9000 German patients with MS. Eur J Neurol: 2011; 18 1036 1045
33. Giovannoni G, Rhoades RW. Individualizing treatment goals and interventions for people with MS. Curr Opin Neurol: 2012; 25 01 S20 S27
34. Fox EJ, Rhoades RW. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Curr Opin Neurol: 2012; 25 01 S11 S19
35. Kappos L, Arnason BGW, Comi G et al. High proportion of patients free from disease activity in all 3 arms of the high-dose Betaferon trial. Presented at the Annual Meeting of the European Neurological Society; June 7-11,: 2008; Nice, France
36. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care: 1992; 30 473 483
37. Cutter GR, Baier ML, Rudick RA et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain: 1999; 122 871 882
38. Kaufman M, Moyer D, Norton J. The significant change for the Timed 25-foot Walk in the multiple sclerosis functional composite. Mult Scler: 2000; 6 286 290
39. Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler: 2008; 14 383 390
40. Krupp LB, LaRocca NG, Muir-Nash J et al. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol: 1989; 46 1121 1123
41. Tombaugh TN. A comprehensive review of the Paced Auditory Serial Addition Test (PASAT). Arch Clin Neuropsychol: 2006; 21 53 76
42. Rao SM. A manual for the Brief Repeatable Battery of neuropsychological tests in multiple sclerosis. Milwaukee, Wisconsin Medical College of Wisconsin: 1990
43. Drake AS, Weinstock-Guttman B, Morrow SA et al. Psychometrics and normative data for the Multiple Sclerosis Functional Composite: replacing the PASAT with the Symbol Digit Modalities Test. Mult Scler: 2010; 16 228 237
44. MSTKG Immunmodulatorische Stufentherapie der Multiplen Sklerose - Neue Aspekte und praktische Umsetzung. Nervenarzt: 2002; 73 556 563
45. Sailer M, Fazekas F, Gass A et al. Zerebrale und spinale MRT-Untersuchungen bei Patienten mit klinisch isoliertem Syndrom oder gesicherter Multipler Sklerose. Fortschr Röntgenstr: 2008; 180 1 8
46. Richert ND, Kryscio RJ. Does one guideline fit all? Neurology: 2011; 77 2080 2081
47. Sämann PG, Knop M, Golgor E et al. Brain Volume and Diffusion Markers as Predictors of Disability and Short-Term Disease Evolution in Multiple Sclerosis. Am J Neuroradiol: 2012; Mar 1. [Epub ahead of print]
48. Benedict RH, Zivadinov R. Risk factors for and management of cognitive dysfunction in multiple sclerosis. Nat Rev Neurol: 2011; 7 332 342
49. Deloire MS, Ruet A, Hamel D et al. MRI predictors of cognitive outcome in early multiple sclerosis. Neurology: 2011; 76 1161 1167
50. Río J, Comabella M, Montalban X. Predicting responders to therapies for multiple sclerosis. Nat Rev Neurol: 2009; 5 553 560
51. Freedman MS, Patry DG, Grand'Maison F et al. Canadian MS Working Group Treatment optimization in multiple sclerosis. Can J Neurol Sci: 2004; 31 157 168
52. Polman CH, Bertolotto A, Deisenhammer F et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol: 2010; 9 740 750
53. Meier F, Schöffski O, Neundörfer B et al. Economic Analysis of a Neuromuscular Health-Care Centre - Opportunities and Risks of § 116 b Code of Social Law (SGB) V. Akt Neurol: 2010; 37 467 473